BullFrog AI Holdings, Inc., through its subsidiaries, operates as a digital biopharmaceutical company that focuses on artificial intelligence and machine learning (AI/ML) driven analysis of data sets in medicine and healthcare in the United States. It offers bfLEAP, an AI/ML platform for the analysis of preclinical and/or clinical data. The company also has licensing agreements with George Washington University for rights to use siRNA targeting Beta2-spectrin in the treatment of human diseases, including hepatocellular carcinoma, obesity, non-alcoholic fatty liver disease, and non-alcoholic steatohepatitis; and Johns Hopkins University for the use of a formulation of Mebendazole for the treatment of human cancer or neoplastic disease. BullFrog AI Holdings, Inc. was founded in 2017 and is based in Gaithersburg, Maryland.

Bullfrog AI Holdings, Inc. Common Stock

BullFrog AI (NASDAQ: BFRG) is a technology-enabled life science company using advanced artificial intelligence (AI) to usher in the next generation of lifesaving therapies. With our leading-edge platform, bfLEAP™, we aid in accelerating and de-risking drug discovery and clinical development using one of the industry’s most advanced graph analytic AI technologies. 

The Problem:

The drug development landscape is littered with failed products and unrealized ROI — all while patients are desperately waiting for treatments that often don’t come: 

•	The cost of bringing a drug to market is $.8 to $2.8 billion
•	Almost 90% of drugs don’t get there
•	The average time to market is 8.5 YEARS

Our Solution:

We’re applying machine learning and AI in drug development to identify new potential therapeutic targets, optimize clinical trials, rescue and repurpose drugs for new indications, and discover new drug targets. By identifying hidden relationships in clinical data, we aim to mitigate risk and elevate the trajectory of precision medicine. 

Our Technology:

The bfLEAP™ platform delivers in a way that neural network models cannot: Explainable AI. We use network models in an interactive graph machine learning format to display and explain your data insights with confidence. Say goodbye to “black box” processing and say hello to AI outputs you can explore and understand. 

Join Us in Our Mission:

With our platform’s superior capabilities, a high-powered team of industry experts, and a pipeline of exclusive in-licensed assets for clinical development, BullFrog AI is pushing the boundaries of AI-assisted drug development. Make BullFrog AI an extension of your organization and clear your analytical barriers.

Leap into the next generation of drug development with BullFrog AI.

TEDCO

BullFrog AI

At BullFrog AI, we've always believed in the power of data-driven innovation. Today, we're excited to spotlight our strategic partnership with the Lieber Institute for Brain Development (LIBD), a pioneer in the field of neuropsychiatric research.

LIBD boasts the world's largest repository of postmortem brains, a treasure trove for understanding the complexities of the human brain. 

But what does this mean to clients?

•	bfLEAP™ can ingest proprietary datasets to potentially accelerate CNS initiatives.
•	We’re positioned to leverage cutting-edge insights from LIBD data.

Stay tuned!

https://bullfrogai.com/

See Dr. Kristi Bigos at the WinterBrain Conference


https://winterbrain.org/
Join us this year for the 2024 Winter Conference on Brain Research in Breckenridge, Colorado with all scientific activities taking place at the Beaver Run Resort & Convention Center.

Traditional scientific panels are scheduled from 7:30 to 9:30 a.m., 4:30 to 6:30 p.m., and 7:00 to 8:30 p.m. to accommodate 6-8 simultaneous research tracks. The schedule allows ample time for informal discussions during outdoor activities on and off the mountain. Everyone is welcome to attend Winter Brain, either as a presenter or attendee.

#bullfrogai #KristiBigos #WinterBrain

GAITHERSBURG, Md., Jan. 17, 2024 -- BullFrog AI Holdings, Inc. (NASDAQ: BFRG; BFRGW), a technology-enabled drug development company using AI and machine learning to enable the successful development of pharmaceuticals and biologics, today announced early results from its collaboration with the Lieber Institute for Brain Development (LIBD) that could revolutionize the understanding and treatment of psychiatric disorders. The early findings from this global strategic partnership have successfully stratified brain expression data, offering what may turn out to be unprecedented insights into psychiatric conditions.

Click here to read more: https://lnkd.in/guMRKWRY

#bullfrogai #LIBD #AIdrugdiscovery

GAITHERSBURG, Md., Jan. 16, 2024 -- BullFrog AI Holdings, Inc. (NASDAQ: BFRG; BFRGW), a technology-enabled drug development company using AI and machine learning to enable the successful development of pharmaceuticals and biologics, today announced that the Australian Patent Office has issued Patent No. 2019216757 protecting the Company’s novel prodrugs derived from mebendazole and their use in treating cancers and other diseases. This follows the July 2023 announcement of the issuance of U.S. Patent No. 11,712,435 for this invention (link), with issuance of patents expected in additional territories in the future.
Click here to learn more: https://lnkd.in/eWd2MMn7

#bullfrogai #AIdrugdevelopment #oncology

Join us as Vin Singh, Chief Executive Officer of BullFrog AI, presents at the Webull LIVE! Healthcare Webinar on Wednesday, January 17, 2024.

Register here: https://lnkd.in/gu2P3WWh


#BullFrogAI #WebullLIVE #VinSingh #DigitalHealth #ArtificialIntelligence #Healthtech #FutureofHealthcare #Innovation

Meet with Vin Singh, CEO of BullFrog AI at the JP Morgan Healthcare Conference in San Francisco! Learn about out unique approach to AI and machine learning using graph analytics, and our recent partnership with the Lieber Institute for Brain Development, including the largest postmortem brain tissue repository in the world, including transcriptomic, genomic, DNA methylation, cell-line, clinical, and imaging data. 

Click here to connect with Vin at JPM: https://lnkd.in/ehACXqbX

#JPMorgan #BullFrogAI #VinSingh #AI #graphanalytics

GAITHERSBURG, Md., Dec. 29, 2023 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ: BFRG; BFRGW) ("BullFrog AI" or the "Company"), a technology-enabled drug development company using artificial intelligence (AI) and machine learning to enable the successful development of pharmaceuticals and biologics, issued a letter to shareholders from its CEO Vin Singh.
https://lnkd.in/ddKnBWbr

#BullFrogAI #pharmaceuticaldevelopment #artificialintelligence #machinelearning #technology #drugdevelopment #shareholderletter #CEOupdate #innovation

Happy New Year!! from the BullFrog AI Team!

Happy Holidays from the BullFrog AI Team!!!

We will be closed on December 25th and January 1st.

NASDAQ:BFRG

Bullfrog AI Holdings, Inc.

Last Close

3.22

26/07 20:00

Market Cap

12.64M

Beta: -

Volume Today

563.32K

Avg: 2.29M

PE Ratio

−5.28

PFCF: −5.00

locale

market

industry

website

ipo date

peer of

Earnings

Earnings per Share (Estimate*)

Revenue (Estimate*)

Metrics